US Pharmacopeia develops and improves its class approach for ensuring quality biopharmaceuticals.
Tina S. Morris, PhD
Advertisement
Tina S. Morris, PhD, is vice president of Biologics & Biotechnology at United States Pharmacopeia (USP)
Articles by Tina S. Morris, PhD
USP is advancing efforts to develop a guidance for evaluating bioassays.
Modern bioassays enable more accurate potency testing.
Advertisement
Latest Updated Articles
USP Product-Class Standards for BiologicsPublished: March 1st 2011 | Updated:
Industry Input Needed on Bioassay StandardsPublished: July 1st 2010 | Updated:
Biological Potency Assays are Key to Assessing Product ConsistencyPublished: June 1st 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
